Skip to main content
SpringerLink
Log in

Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Among the different forms of allergic conjunctivitis, atopic keratoconjunctivitis has distinct characteristics, defined by a more common onset in late adolescence or early adulthood, but also affecting the elderly, and with a higher prevalence in male individuals. However, the prevalence of atopic keratoconjunctivitis is scarcely investigated, and the data are often uncertain because other allergic nasal or respiratory disorders occur concomitantly. Mast cells, eosinophils, basophils, and T cells are involved in the pathogenesis of atopic keratoconjunctivitis. Despite its denomination as atopic, negative responses to skin tests or in-vitro immunoglobulin E tests are common. In fact, atopic keratoconjunctivitis can be attributed to a combination of T-helper-1 and T-helper-2 responses, but a higher prominence for T-helper-1 cells was found. The most common symptoms of atopic keratoconjunctivitis are bilateral ocular itching, burning, and tearing with a perennial presentation, although some patients may have seasonal exacerbations in winter or summer. Other symptoms such as photophobia, blurred vision, and mucous chewy discharge, owing to the accumulation of cells and mucin, may occur. The diagnosis of atopic keratoconjunctivitis is mainly clinical, as accepted diagnostic criteria or laboratory tests are not available. The treatment of atopic keratoconjunctivitis is aimed at controlling symptoms, decreasing relapse and exacerbations, and reducing vision loss. Therapeutic options comprise topical ophthalmic drops, including cromones, antihistamines, corticosteroids, and calcineurin inhibitors. Topical ointments are also available for corticosteroids and calcineurin inhibitors. Severe forms may require systemic medications including antihistamines, corticosteroids, and calcineurin inhibitors. Atopic keratoconjunctivitis therapy in the elderly does not differ from the adult population, but the occurrence of multi-morbidities and concomitant drug treatment, which are common in this age group, requires a careful evaluation to determine appropriate and personalized treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hogan MJ. Atopic keratoconjunctivitis. Am J Ophthalmol. 1953;36(71):937–47.

    Article  CAS  PubMed  Google Scholar 

  2. Bonini S, Gramiccioni C, Bonini M, Bresciani M. Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review. Curr Opin Allergy Clin Immunol. 2007;7(5):446–9.

    Article  PubMed  Google Scholar 

  3. Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: a review. J Am Acad Dermatol. 2014;70(3):569–75.

    Article  PubMed  Google Scholar 

  4. Yoneda K, Okamoto H, Wada Y, Morita K, Takahashi M, Ogura Y, et al. Atopic retinal detachment: report of four cases and a review of the literature. Br J Dermatol. 1995;133(4):586–91.

    Article  CAS  PubMed  Google Scholar 

  5. Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988–1994. J Allergy Clin Immunol. 2010;126(4):778–83.

    Article  PubMed  Google Scholar 

  6. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000;06(6):1019–32.

    Article  Google Scholar 

  7. Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 1990;97(8):992–1000.

    Article  CAS  PubMed  Google Scholar 

  8. Trocme SD, Bonini S, Barney NP, Bloch KJ, Allansmith MR. Late-phase reaction in topically induced ocular anaphylaxis in the rat. Curr Eye Res. 1988;7(5):437–43.

    Article  CAS  PubMed  Google Scholar 

  9. Oshinskie L, Haine C. Atopic dermatitis and its ophthalmic complications. J Am Optom Assoc. 1982;53(11):889–94.

    CAS  PubMed  Google Scholar 

  10. Rich LF, Hanifin JM. Ocular complications of atopic dermatitis and other eczemas. Int Ophthalmol Clin. 1985;25(1):61–76.

    Article  CAS  PubMed  Google Scholar 

  11. Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-gamma, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin Exp Allergy. 2000;30(1):103–9.

    Article  CAS  PubMed  Google Scholar 

  12. Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10(5):478–85.

    Article  CAS  PubMed  Google Scholar 

  13. Calder VL, Jolly G, Hingorani M, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy. 1999;29(9):1214–22.

    Article  CAS  PubMed  Google Scholar 

  14. Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007;7(5):429–35.

    Article  CAS  PubMed  Google Scholar 

  15. Bonini S. Atopic keratoconjunctivitis. Allergy. 2004;59(Suppl. 78):71–3.

    Article  PubMed  Google Scholar 

  16. Nivenius E, Van der Ploeg I, Gafvelin G, et al. Conjunctival provocation with airborne allergen in patients with atopic keratoconjunctivitis. Clin Exp Allergy. 2012;42(1):58–65.

    Article  CAS  PubMed  Google Scholar 

  17. Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin N Am. 2010;30(3):323–36.

    Article  Google Scholar 

  18. Metz DP, Hingorani M, Calder VL, Buckley RJ, Lightman SL. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol. 1997;100(6 Pt 1):817–24.

    Article  CAS  PubMed  Google Scholar 

  19. Ding W, Zou GL, Zhang W, et al. Interleukin-33: its emerging role in allergic diseases. Molecules. 2018. https://doi.org/10.3390/molecules23071665.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lin J, Zhao GQ, Wang Q, et al. Regulation of interleukin 33/ST2 signaling of human corneal epithelium in allergic diseases. Int J Ophthalmol. 2013;6:23–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology. 2003;110(3):487–92.

    Article  PubMed  Google Scholar 

  22. Yamagami S, Ebihara N, Amano SY. Chemokine receptor gene expression in giant papillae of atopic keratoconjunctivitis. Mol Vis. 2005;11:192–200.

    CAS  PubMed  Google Scholar 

  23. Kitaichi N, Shimizu T, Honda A, et al. Increase in macrophage migration inhibitory factor levels in lacrimal fluid of patients with severe atopic dermatitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(7):825–8.

    Article  PubMed  Google Scholar 

  24. Yasuda C, Enomoto A, Ishiwatari S, et al. Macrophage migration inhibitory factor (MIF) in the stratum corneum: a marker of the local severity of atopic dermatitis. Exp Dermatol. 2014;23(10):764–6.

    Article  PubMed  Google Scholar 

  25. Zhan H, Smith L, Calder V, Buckley R, Lightman S. Clinical and immunological features of atopic keratoconjunctivitis. Int Ophthalmol Clin. 2003;43(1):59–71.

    Article  PubMed  Google Scholar 

  26. Tuft SJ, Ramakrishnan M, Seal DV, Kemeny DM, Buckley RJ. Role of Staphylococcus aureus in chronic allergic conjunctivitis. Ophthalmology. 1992;99(2):180–4.

    Article  CAS  PubMed  Google Scholar 

  27. Dogru M, Nakagawa N, Tetsumoto K, Katakami C, Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol. 1999;43(1):53–7.

    Article  CAS  PubMed  Google Scholar 

  28. Leonardi A, Borghesan F, Faggian D, Depaoli M, Secchi AG, Plebani M. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000;129(2):151–8.

    Article  CAS  PubMed  Google Scholar 

  29. Tanaka M, Dogru M, Takano Y, et al. The relation of conjunctival and corneal findings in severe ocular allergies. Cornea. 2004;23(5):464–7.

    Article  PubMed  Google Scholar 

  30. Easty D, Entwistle C, Funk A, Witcher J. Herpes simplex keratitis and keratoconus in the atopic patient: a clinical and immunological study. Trans Ophthalmol Soc U K. 1975;95(2):267–76.

    CAS  PubMed  Google Scholar 

  31. Ingram RM. Retinal detachment associated with atopic dermatitis and cataract. Br J Ophthalmol. 1965;49:96–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin Dermatol. 2008;9(4):233–44.

    Article  PubMed  Google Scholar 

  33. Wakamatsu TH, Okada N, Kojima T, Matsumoto Y, Ibrahim OM, Dogru M, et al. Evaluation of conjunctival inflammatory status by confocal scanning laser microscopy and conjunctival brush cytology in patients with atopic keratoconjunctivitis (AKC). Mol Vis. 2009;15:1611–9.

    PubMed  PubMed Central  Google Scholar 

  34. Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352.

    Article  PubMed  Google Scholar 

  35. Cardona V, Guilarte M, Luengo O, Labrador-Horrillo M, Sala-Cunill A, Garriga T. Allergic diseases in the elderly. Clin Transl Allergy. 2011;1(1):11.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12(6):485–94.

    Article  CAS  PubMed  Google Scholar 

  37. Shaker M, Salcone E. An update on ocular allergy. Curr Opin Allergy Clin Immunol. 2016;16(5):505–10.

    Article  CAS  PubMed  Google Scholar 

  38. Simons FE, Fraser TG, Maher J, Pillay N, Simons KJ. Central nervous system effects of H1-receptor antagonists in the elderly. Ann Allergy Asthma Iimmunol. 1999;82(2):157–60.

    Article  CAS  Google Scholar 

  39. Breton G, Froissart M, Janus N, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function: the three-city population-based study. Nephrol Dial Transplant. 2011;26(9):2852–9.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med. 2002;113(Suppl. 9A):38s–46s.

    Article  CAS  PubMed  Google Scholar 

  41. Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015;13(1):1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Bousquet J, Ansotegui I, Canonica GW, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012;28(1):131–9.

    Article  CAS  PubMed  Google Scholar 

  43. Sologuren A, Vinas R, Cordon E, et al. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria. Allergy Asthma Proc. 2018;39(4):299–304.

    Article  CAS  PubMed  Google Scholar 

  44. Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;70(Suppl. 100):1–24.

    Article  CAS  PubMed  Google Scholar 

  45. Lyseng-Williamson KA. Oral bepotastine: in allergic disorders. Drugs. 2010;70(12):1579–91.

    Article  CAS  PubMed  Google Scholar 

  46. Bielory L, Schoenberg D. Emerging therapeutics for ocular surface disease. Curr Allergy Asthma Rep. 2019;19(3):16.

    Article  PubMed  Google Scholar 

  47. Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res. 2008;33(7):545–9.

    Article  CAS  PubMed  Google Scholar 

  48. Flammiger A, Maibach H. Drug dosage in the elderly: dermatological drugs. Drugs Aging. 2006;23(3):203–15.

    Article  CAS  PubMed  Google Scholar 

  49. Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996;47(6):1396–402.

    Article  CAS  PubMed  Google Scholar 

  50. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Int Med. 2002;17(9):717–20.

    Article  Google Scholar 

  51. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116(4):652–7.

    Article  PubMed  Google Scholar 

  52. Weinstein RS. Clinical practice: glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.

    Article  CAS  PubMed  Google Scholar 

  53. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord. 1983;5(4):319–32.

    Article  CAS  PubMed  Google Scholar 

  54. Hall RC, Popkin MK, Stickney SK, Gardner ER. Presentation of the steroid psychoses. J Nerv Ment Dis. 1979;167(4):229–36.

    Article  CAS  PubMed  Google Scholar 

  55. Ezeamuzie CI. Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. Int J Iimmunopharmacol. 1996;18(4):263–70.

    Article  CAS  Google Scholar 

  56. Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90(4):461–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Tesse R, Spadavecchia L, Fanelli P, et al. Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol. 2010;21(2 Pt 1):330–5.

    Article  PubMed  Google Scholar 

  58. Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105(9):1715–20.

    Article  CAS  PubMed  Google Scholar 

  59. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–41.

    Article  PubMed  Google Scholar 

  60. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008;115(6):988-92.e5.

    Article  Google Scholar 

  61. Hoang-Xuan T, Prisant O, Hannouche D, Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology. 1997;104(8):1300–5.

    Article  CAS  PubMed  Google Scholar 

  62. Stumpf T, Luqmani N, Sumich P, Cook S, Tole D. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea. 2006;25(10):1147–9.

    Article  PubMed  Google Scholar 

  63. Jabbehdari S, Starnes TW, Kurji KH, Eslani M, Cortina MS, Holland EJ, et al. Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis. Ocul Surf. 2018. https://doi.org/10.1016/j.jtos.2018.12.002 (Epub ahead of print).

    Article  PubMed  Google Scholar 

  64. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32.

    Article  CAS  PubMed  Google Scholar 

  65. Gangaputra S, Newcomb CW, Liesegang TL. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Galor A, Jabs DA, Leder HA. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–32.

    Article  PubMed  Google Scholar 

  68. Hornbeak DM, Thorne JE. Immunosuppressive therapy for eye diseases: effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol. 2015;5(4):156–63.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Allergy and Clinical Immunology, Department of Medicine and Surgery, University of Parma, Via Gramsci n.14, 43126, Parma, Italy

    Erminia Ridolo, P. Kihlgren, I. Pellicelli, M. C. Nizi & F. Pucciarini

  2. Cardiac/Pulmonary Rehabilitation Unit, ASST Pini-CTO, Milan, Italy

    C. Incorvaia

Authors
  1. Erminia Ridolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Kihlgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Pellicelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. C. Nizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Pucciarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Incorvaia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erminia Ridolo.

Ethics declarations

Funding

No funding was received for the preparation of this article.

Conflict of interest

Erminia Ridolo, Kihlgren P, Pellicelli I, Nizi MC, Pucciarini F, and Incorvaia C have no conflicts of interest that are directly relevant to the content of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ridolo, E., Kihlgren, P., Pellicelli, I. et al. Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly. Drugs Aging 36, 581–588 (2019). https://doi.org/10.1007/s40266-019-00676-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-019-00676-7

Search

Navigation